• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Banks
    Finance
    Savings Institutions
    Finance
    Get the next $BHLB alert in real time by email

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT).

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date 

    Index Name 

    Action 

    Company Name 

    Ticker 

    GICS Sector 

    September 2, 2025 

    S&P MidCap 400 

    Addition 

    Elanco Animal Health 

    ELAN 

    Health Care 

    September 2, 2025 

    S&P MidCap 400

    Deletion 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600 

    Addition 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600

    Deletion

    Brookline Bancorp

    BRKL

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600-302539403.html

    SOURCE S&P Dow Jones Indices

    Get the next $BHLB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHLB
    $BRKL
    $ELAN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:43:49 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:43:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:31:49 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Schedules First Quarter 2026 Earnings Announcement and Conference Call for Tuesday, April 28, 2026

    NEW YORK, March 26, 2026 /PRNewswire/ -- S&P Global's (NYSE:SPGI) first quarter 2026 results will be issued on Tuesday, April 28, 2026 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on April 28, 2026 to discuss the Company's first quarter 2026 financial results.The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck, and

    3/26/26 10:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces: Mobility Global to Host Investor Day on May 12, 2026

    NEW YORK, March 25, 2026 /PRNewswire/ -- S&P Global Inc. (NYSE:SPGI) announced today that its Mobility division ("Mobility Global") will host its inaugural Investor Day on May 12, 2026, in New York City, as it prepares for its planned separation from S&P Global into a standalone public company in mid-2026. Bill Eager, President of S&P Global Mobility and Chief Executive Officer of Mobility Global, will be joined by Matt Calderone, Chief Financial Officer-designate of Mobility Global, and other senior leaders to present the company's strategy, positioning, and financial framework

    3/25/26 9:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

    In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at 8:30 a.m. Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorabl

    3/25/26 8:05:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    3/26/26 6:05:56 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sarepta Therapeutics Inc.

    10-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    3/2/26 7:02:15 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    2/25/26 5:09:54 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P Global Schedules First Quarter 2026 Earnings Announcement and Conference Call for Tuesday, April 28, 2026

    NEW YORK, March 26, 2026 /PRNewswire/ -- S&P Global's (NYSE:SPGI) first quarter 2026 results will be issued on Tuesday, April 28, 2026 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on April 28, 2026 to discuss the Company's first quarter 2026 financial results.The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck, and

    3/26/26 10:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces: Mobility Global to Host Investor Day on May 12, 2026

    NEW YORK, March 25, 2026 /PRNewswire/ -- S&P Global Inc. (NYSE:SPGI) announced today that its Mobility division ("Mobility Global") will host its inaugural Investor Day on May 12, 2026, in New York City, as it prepares for its planned separation from S&P Global into a standalone public company in mid-2026. Bill Eager, President of S&P Global Mobility and Chief Executive Officer of Mobility Global, will be joined by Matt Calderone, Chief Financial Officer-designate of Mobility Global, and other senior leaders to present the company's strategy, positioning, and financial framework

    3/25/26 9:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, March 24, 2026 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Wednesday, April 1, 2026. S&P/TSX Canadian Dividend Aristocrats Index – April 1, 2026SymbolCOMPANYDELETEDGSYgoeasy Ltd.For more information about S&P Dow Jones Indices, please visit www.spdji.comABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are inv

    3/24/26 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 5:09:10 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 10:03:30 AM ET
    $BRKL
    Savings Institutions
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    S&P Global Appoints Chief Strategy Officer for Mobility Global Completing New Executive Leadership Team

    Martin Metzker to lead Strategy, Communications and Enterprise Marketing for Mobility Global in preparation for its planned separation into a standalone public companyNEW YORK, Feb. 19, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the appointment of Martin Metzker as Chief Strategy Officer of S&P Global Mobility ("Mobility Global"), effective immediately. Mr. Metzker will be responsible for leading Mobility Global's Strategy function and overseeing Communications and Enterprise marketing for the business as it prepares for its planned separation from S&P Global into a standalone public company. Mr. Metzker joins the company from Boston Consulting Group, and will report to Bil

    2/19/26 4:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance